Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C
RA Capital leads round to advance two programs towards IND
A crossover-heavy syndicate for Kinnate’s series C suggests an IPO could be on the horizon.
The presence of half a dozen crossover investors in Kinnate’s $98 million series C round suggests an IPO could be the next financing for the precision oncology company.
If it does go public this year before its